Author:
Stalman Eileen,Wieske Luuk,Keijser Jim,van Dam Koos,Kummer Laura,Wilbrink Maarten F.,van Kempen Zoé,Killestein Joep,Volkers Adriaan G.,Tas Sander,Boekel Laura,Wolbink Gertjan,van der Kooi Anneke J.,Raaphorst Joost,Löwenberg Mark,Takkenberg R. Bart,D'Haens Geert R.A.M.,Spuls Phyllis I.,Bekkenk Marcel W.,Musters Annelie H.,Post Nicoline F.,Bosma Angela L.,Hilhorst Marc L.,Vegting Yosta,Bemelman Frederike J.,Voskuyl Alexandre,Broens Bo,Sanchez Agner Parra,van Els Cecile,de Wit Jelle,Rutgers Abraham,de Leeuw Karina,Horváth Barbara,Verschuuren Jan J.G.M.,Ruiter Annabel M.,van Ouwerkerk Lotte,van der Woude Diane,Allaart Cornelia F.,Teng Onno YK,van Paassen Pieter,Busch Matthias,Brusse Esther,van Doorn Pieter,Baars Adája E.,Hijnen Dirk Jan,Schreurs Corine R.G.,van der Pol Ludo,Goedee H. Stephan,Steenhuis Maurice,Keijzer Sofie,Cristianawati Olvi,ten Brinke Anja,Verstegen Niels,Zwinderman Aeilko H.,van Ham Marieke,Rispens Theo,Welkers Matthijs R.A.,Jonges Marcel,Eftimov Filip,Kuijpers Taco
Reference31 articles.
1. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands;B De Gier;Euro Surveill,2021
2. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance;J Chen;J Chem Inf Model,2022
3. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease;R H Haberman;Ann Rheum Dis,2021
4. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?;Z L E Van Kempen;Mult Scler Relat Disord,2022
5. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study;L Wieske;Lancet Rheumatol,2022